mifepristone has been researched along with metapristone in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ecker, GF; Haslinger, E; Hödl, C; Kunert, O; Raunegger, K; Schramm, HW; Seger, C; Steiner, R; Strauss, WS; Strommer, R; Sturm, S | 1 |
| Goessler, W; Haslinger, E; Hödl, C; Kunert, O; Leitner, A; Saha, P; Schramm, HW; Steiner, R; Strauss, WS | 1 |
| Chen, C; Chen, H; Gao, Y; Huang, J; Lin, Y; Liu, R; Liu, S; Ye, J; Zhang, Y; Zhao, P; Zheng, Z; Zhou, J | 1 |
| Ferguson, J; Hill, NC; MacKenzie, IZ; Selinger, M | 1 |
| Barre, J; Grimaldi, B; Hamberger, C; Tillement, JP; Tremblay, D | 1 |
| Fotherby, K; He, CH; Shi, YE; Van Look, PF; Xu, JQ; Ye, ZH; Zhang, GQ | 1 |
| Chen, H; Chen, J; Jia, L; Lu, Y; Ou, M; Shao, J; Wan, L; Wang, J; Yu, S; Zhu, Y | 1 |
| Chen, JZ; Gao, Y; Jia, L; Jiang, Z; Shao, JW; Wang, JC; Zeng, RJ; Zhu, YW | 1 |
| Chen, J; Dong, H; Jia, L; Liu, J; Lu, Y; Shao, J; Wang, J; Xiao, Y; Xie, J; Yu, S; Zheng, N; Zhu, Y | 1 |
| Ho, RJ; Jia, L; Li, T; Liu, J; Tu, X; Wan, L; Wang, J; Xiao, Y; Xu, H; Yan, C; Yang, X; Yu, S; Zhu, Y | 1 |
| He, S; Huang, C; Jia, L; Liu, J; Lu, Y; Qin, C; Tian, Z; Yan, C; Yang, X; Yu, S | 1 |
| Chen, H; Chen, J; Jia, L; Li, T; Liu, J; Liu, W; Wang, J; Zheng, N | 1 |
| Chen, J; Jia, L; Liu, J; Liu, W; Wang, J; Zheng, N | 1 |
| Chen, H; Fan, L; Jia, L; Jiang, K; Liu, J; Shao, J; Shen, Z; Zheng, G | 1 |
| Sang, L; Wang, X; Zhao, X | 1 |
| Cheng, Y; Dong, H; Jia, L; Li, B; Liu, J; Liu, W; Nie, H; Wang, J; Zheng, N | 1 |
1 trial(s) available for mifepristone and metapristone
| Article | Year |
|---|---|
Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Female; Humans; Mifepristone; Molecular Structure; Pregnancy | 1993 |
15 other study(ies) available for mifepristone and metapristone
| Article | Year |
|---|---|
Syntheses and antigestagenic activity of mifepristone derivatives.
Topics: Alkaline Phosphatase; Breast Neoplasms; Cell Line, Tumor; Female; Hormone Antagonists; Humans; Mifepristone; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Progesterone; Regression Analysis; Structure-Activity Relationship | 2009 |
Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells.
Topics: Binding Sites; Breast Neoplasms; Cell Line, Tumor; Coordination Complexes; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Mifepristone; Receptors, Progesterone | 2010 |
Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Kruppel-Like Transcription Factors; Male; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, Nude; Mifepristone; Molecular Structure; Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy.
Topics: Abortion, Induced; Adult; Female; Fetal Blood; Humans; Maternal-Fetal Exchange; Mifepristone; Pregnancy; Pregnancy Trimester, Second; Steroids | 1991 |
In vitro study of the binding of RU 486 and RU 42 633 to human serum proteins.
Topics: Blood Proteins; Erythrocytes; Estrenes; Humans; Metabolic Clearance Rate; Mifepristone; Orosomucoid; Progestins | 1989 |
Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486).
Topics: Annexin A5; Anticarcinogenic Agents; Caspase 3; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Membrane Potential, Mitochondrial; Mifepristone; Neoplasm Metastasis; Spectroscopy, Fourier Transform Infrared | 2014 |
A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486).
Topics: Animals; Anticarcinogenic Agents; Chromatography, High Pressure Liquid; Female; Limit of Detection; Male; Mifepristone; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2014 |
In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents.
Topics: Animals; Anticarcinogenic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoprevention; Disease Models, Animal; Female; Integrin alpha4; Liver; Lung Neoplasms; Melanoma, Experimental; Mice, Inbred C57BL; Mifepristone; Treatment Outcome | 2016 |
Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone.
Topics: Abortifacient Agents, Steroidal; Animals; Chemical and Drug Induced Liver Injury; Female; Male; Mifepristone; Rats | 2016 |
Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention.
Topics: Antigens, CD; Blotting, Western; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Cell Survival; Chemoprevention; Down-Regulation; Epithelial-Mesenchymal Transition; Gene Ontology; Human Umbilical Vein Endothelial Cells; Humans; Isotope Labeling; Metabolome; Mifepristone; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Proteomics; Reproducibility of Results; Up-Regulation; Vimentin | 2016 |
Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Chemoprevention; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Peritoneal Neoplasms; Peritoneum; Receptors, CXCR4; Signal Transduction | 2017 |
Metapristone (RU486 derivative) inhibits cell proliferation and migration as melanoma metastatic chemopreventive agent.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Female; G1 Phase; Melanoma; Mice; Mice, Inbred C57BL; Mifepristone; Neoplasm Metastasis; Resting Phase, Cell Cycle; Signal Transduction; Up-Regulation | 2017 |
Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mifepristone; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction | 2017 |
Mifepristone Inhibits the Migration of Cervical Cancer Cells by Inhibiting Exocrine Secretion.
Topics: Aniline Compounds; Apoptosis; Benzylidene Compounds; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Exosomes; Female; HeLa Cells; Humans; Mifepristone; Ubiquitins; Up-Regulation; Uterine Cervical Neoplasms | 2018 |
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemical Phenomena; Drug Compounding; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mifepristone; Nanoparticles; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Xenograft Model Antitumor Assays | 2019 |